Mesenchymal stromal cells for sepsis and septic shock: Lessons for treatment ofCOVID-19
Mesenchymal stromal cells for sepsis and septic shock: Lessons for treatment ofCOVID-19
复制标题
DOI：
10.1002/sctm.20-0239
复制
发表时间：
2020-08-18
影响因子：
6
通讯作者：
Bensoussan, Daniele
中科院分区：
文献类型：
--
作者：
Laroye, Caroline;Gibot, Sebastien;Bensoussan, Daniele
败血症被定义为由宿主对感染的免疫反应失调引起的危及生命的器官功能障碍。严重急性呼吸系统综合征冠状病毒2 （SARS-CoV-2）的出现凸显了这一多因素复杂综合征。由于缺乏针对SARS-CoV-2和这种感染最严重阶段的急性呼吸窘迫综合征（ARDS）的特异性治疗方法，因此需要寻找替代治疗方法。目前正在测试几种治疗方法，其中包括间充质间质细胞。这些细胞已经用于急性呼吸窘迫综合征（ARDS）、败血症和感染性休克的临床前模型，并在少数临床试验中表现出良好的耐受性和前景，但许多问题仍未得到解答。
Sepsis is defined as life-threatening organ dysfunction caused by a deregulated immune host response to infection. The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has highlighted this multifactorial and complex syndrome. The absence of specific treatment neither against SARS-CoV-2 nor against acute respiratory distress syndrome (ARDS), the most serious stage of this infection, has emphasized the need to find alternative treatments. Several therapeutics are currently tested and among them, mesenchymal stromal cells. These cells, already used in preclinical models of ARDS, sepsis, and septic shock and also in few clinical trials appear well-tolerated, promising, but many questions remain unanswered.